Preliminary data from a Phase 3 clinical trial, CheckMate-274, evaluating Bristol Myers Squibb's (NYSE:BMY) PD-1 inhibitor Opdivo (nivolumab) after surgery (adjuvant therapy) in patients with high-risk, muscle-invasive urothelial carcinoma demonstrated that the study met the primary endpoint of disease-free survival (DFS) compared to placebo in the overall study group and in patients with PD-L1-expressing (at least 1%) cancer.
The study will continue as planned to allow for analyses of secondary endpoints, including overall survival and disease-specific survival. The estimated completion date is November 2026.
Compete results will be submitted for presentation at an upcoming medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.